COVID-19, Oral Drugs and Patents in Mexico
Feb/24/2022

COVID-19, Oral Drugs and Patents in Mexico

On February 15, the article "COVID-19, Oral Drugs and Patents in Mexico", written by Citlali Carlos, Elías Rios, Karen Covarrubias and Cesar Ramirez, was published in "Chambers and Partners", a British classification and research company in charge of publishing international lists and guides for the legal industry, based in London, founded in 1989 and recognized for its high level of expertise in the industry.

The article describes a different point of view about COVID-19, which emphasizes patents and how to protect research done by experts.

 

COVID-19, Oral Drugs and Patents in Mexico

 

With the exponential growth of the pandemic worldwide, new, safer and rapid treatments are needed to reduce the risk of the progression of the novel coronavirus (COVID-19).

Scientific literature reveals that monoclonal antibodies are currently authorised treatments for at-risk outpatients with COVID-19.

However, said antibodies require administration by means of infusion or injection in a medical setting. Thus, oral agents, such as molnupiravir, may be more practical and patient-friendly for non-hospitalised persons, as they can be administered by the patient at home shortly after diagnosis and their mechanism is independent of mutations in the spike protein of the virus.

In its very first communication of 2022, the Mexican Regulatory Agency (COFEPRIS) announced that the Mexican government had authorised the use of molnupiravir.

 

Molnupiravir

Molnupiravir is an oral, small-molecule antiviral prodrug (ie, one that, after administration, is metabolised into a pharmacologically active drug) that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COFEPRIS recently authorised the oral treatment molnupiravir to be used to treat patients with mild or moderate COVID-19, and those with a high risk of complications.

The approval process began the week of 23 December 2021, when technical information was exchanged with other regulatory agencies; this knowledge transfer process was carried out thanks to regulatory convergence, declared a priority in COFEPRIS in August of last year.

This treatment (on a controlled emergency basis) does not replace the authorised vaccines against COVID-19, and it should not be used without medical indication.

 

How it works?

Specialised personnel of the Healthcare Authorisation Commission evaluated the submitted evidence presented by manufacturers certifying compliance with the necessary requirements to guarantee quality, safety and efficacy.

Based on the available studies, COFEPRIS determined that this treatment may be authorised for emergency use for the following therapeutic indications:

  • treatment of mild to moderate COVID-19 symptoms;
  • in adults with a positive SARS-cov-2 diagnostic test;
  • where supplemental oxygen is not required;
  • for those who have at least one risk factor for developing severe COVID-19, including hospitalisation or death; and
  • for whom the authorised, alternative COVID-19 treatment options are not accessible or clinically appropriate.

The drug works by introducing errors into the genetic code of the SARS-CoV-2 virus, preventing it from replicating in the body. It is an oral medication supplied through capsules for a period of five days.

 

The role of IP

With a growing range of COVID-19 vaccines and other products coming online, the international community is targeting universal access. This, however, reveals new challenges related to the protection for inventions and inventors.

The Medicines Patent Pool is an initiative that links up interested parties to promote the voluntary licensing practices of pharmaceutical companies, helping the IP-owner enterprises link up with local partners who can widen production and distribution of medical technologies.

Here is where “licensing” comes to the spotlight.

In a licence agreement (a tool for transferring IP) the licensor grants authorisation to a company that has manufacturing capacity and distribution channels to bring the invention to potential users. In other words, the owner of the IP, or the entity that controls the use, allows third parties to develop, manufacture and/or distribute the invention.

The standard licensing model allows a licensor to receive a royalty fee under the agreed financial terms of the agreement.

 

What about open science?

UNESCO has established that “open science” has the potential to make the scientific process more transparent, inclusive and democratic; and also that it is increasingly recognised as a critical accelerator for the achievement of the United Nations’ Sustainable Development Goals and a true game-changer in filling the science, technology and innovation gaps and fulfilling the human right to science.

Nevertheless, it is necessary to bear in mind that intellectual property is a critical ingredient in solving pressing problems as the bridge allowing diverse parties to work together with clarity, by providing a legal basis for production at large scale and within an efficient timeframe to satisfy demand in a public health emergency.

Common market failures are related to the limited capacity to manufacture the invention in the necessary quantities and the risk of concentrating distribution of the invention only in those places where users can pay a premium.

At its most basic, IP ownership allows technology transfer and derived agreements to offer effective instruments that regulate the collaborative process to reach scientific findings from creators, such as research institutions and universities, or business labs, to public and private users, with the goal of transforming inventions and scientific outcomes into new innovative products that benefit society.

Technology transfer also fosters the multiplication of certain much-needed inventions, such as new pharmaceutical products.

 

“Emergency”

The official press release launched by COFEPRIS highlights “emergency conditions”.

The Mexican government has issued decrees defining what should be considered a “health emergency” (force majeure, epidemic, etc) and COFEPRIS is entitled to analyse, in accordance with the applicable legal framework, the relevance of reducing the documents required in the equivalence agreements, as well as to granting applicants the registration of health supplies in a shorter period than that mentioned in previous equivalence agreements.

The authorisation for “emergency” use is issued in a controlled manner and requires a medical prescription, considering the details in the authorisation letter to avoid misuse of this drug, self-medication and/or its irregular sale.

 

“Collateral damage”

COVID has brought the world face-to-face with a scenario where respiratory medications are the tip of the iceberg. As lockdowns and restrictions relax in several locations globally, some people are finding it challenging to get back to “normal” life. Going back out and mingling with other people is a concept that is causing an uptick in fear and anxiety.

Behavioural therapy and medications for treating anxiety, or depression can help those experiencing significant difficulties with this unique and evolving mental health challenge.

Medicines against anxiety and antidepressants are some of the most demanded in the current health crisis and it is necessary to analyse their place as a necessary resource to face this challenge.

 

Mexican scenario

In the past 20 years, the Mexican regulatory framework has radically changed. While in other countries – such as Canada, Australia and Switzerland – it is in the process of being analysed, Mexico is part of a group of countries authorising the drug in record time by arguing that other regulatory agencies have scientific evidence that this oral therapeutic option as safe and effective.

In addition, legal amendments allowing linkage between healthcare registrations and patents of substance or active ingredient, and the signing of the United States–Mexico–Canada Agreement (T-MEC), opening the possibility of patents for second medical use, together with the possibility of granting adjustments to the duration of patents unreasonably delayed, make Mexico an attractive destination to invest in the pharmaceutical industry.

The above is confirmed by an overall scenario of 12 Free Trade Agreements with 46 countries, 32 Agreements for the Reciprocal Protection of Investments with 33 countries and nine agreements within the framework of the Latin American Integration Association, setting the conditions for major transnational companies that have announced multimillion dollar investments in the upcoming years in Mexico to expand their capacity and modernise their plants, in addition to continuing their clinical research and launching new products.

This creates an obligation and an opportunity for the state – and most likely for private advisors too – to set an appropriate health policy and guarantee the population’s access to medicines. This is not only a question of regulation, but of efficiency. Accepted medicines are of little use if they are not accessible to the population.

In closing, Mexico is an attractive destination to invest in the pharmaceutical industry, which coupled with the current COVID-19 pandemic, suggests sustained growth in the coming years for the pharmaceutical industry.

 

Article by: 

Citlali Carlos

citlali.carlos@vila.com.mx

Karen Covarrubias

karen.covarrubias@vila.com.mx

Cesar Ramirez

cesar@vila.com.mx

Elias Rios

rios.elias@vila.com.mx

Chat With Us